1. Introduction {#s0005}
===============

Takotsubo cardiomyopathy (TTC) is characterized by transient regional wall motion abnormalities (WMA) of the cardiac ventricle(s), and is causally unrelated to coronary artery pathology [@bb0005]. Although there is no universally accepted definition of TTC, the revised Mayo Clinic Criteria have been used most commonly [@bb0005]. Those criteria state that TTC is transient hypokinesis, akinesis or dyskinesis of the left mid-ventricular segments with or without apical involvement [@bb0005]. Meanwhile, a TTC variant, characterized by hypocontractile mid-ventricular segments and a hypercontractile apex, is known and designated as either reverse TTC (r-TTC) or inverted TTC [@bb0010], [@bb0015], [@bb0020]. Plasma catecholamine (epinephrine/norepinephrine) levels are highly elevated in patients with both TTC and r-TTC, and sympathetic nervous system over-activity has been implicated as a common etiological mechanism [@bb0010], [@bb0015], [@bb0020]. Several authors have attempted to identify potential differences between TTC and r-TTC unrelated to neurological diseases, and reported several differences [@bb0015], [@bb0020]. Meanwhile, other authors have argued that TTC and r-TTC may be a temporal evolution of the same disease, based on patients who developed r-TTC several weeks to months after an episode of typical TTC [@bb0025], [@bb0030], [@bb0035], [@bb0040]. Therefore, the question of whether TTC is different from r-TTC has not been answered fully. Reverse TTC is also known to develop in patients with severe brain damage, particularly in those with aneurysmal subarachnoid hemorrhage (SAH) [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065]. However, only a few case reports of SAH-induced r-TTC are available in the literature [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065]. This study was conducted to identify possible demographic, physiologic, echocardiographic, electrocardiographic, and neurochemical differences between TTC and r-TTC associated with SAH.

2. Methods {#s0010}
==========

2.1. Patients {#s0015}
-------------

This was a retrospective analysis using data acquired prospectively between January 2009 and December 2014. We prospectively performed the following examinations on aneurysmal SAH patients: transthoracic echocardiography (TTE), 12-lead ECG, and measurements of plasma epinephrine/norepinephrine levels and those of other cardiac biomarkers. All three examinations were completed within 24 h of admission. Follow-up TTEs were performed in selected patients, mostly within 7 days of admission. The decision to perform a follow-up TTE was at the discretion of the attending neuro-intensivist. All TTE images were reviewed by a board-certified cardiologist (EW) and an experienced ultrasound technician (KS). The diagnosis of TTC/r-TTC was based on the revised Mayo Clinic Criteria [@bb0005] and dichotomization was done jointly by the two authors (EW and KS). SAH severity was evaluated using the World Federation of Neurosurgical Societies (WFNS) SAH score [@bb0070]. Concomitant pulmonary edema was diagnosed clinically [@bb0065]. Clinical outcomes are represented by 90-day mortality. This study was approved by the internal review board of our institution, and informed consent was obtained from patients or more often, from their surrogates.

2.2. Echocardiographic/electrocardiographic evaluations {#s0020}
-------------------------------------------------------

For acquisition of TTE, General Electric Vivid 7 (GE Healthcare, Tokyo, Japan) was used. Experienced ultrasound technicians performed all TTE procedures. Left ventricular (LV) dimensions, LV wall thickness, and LV mass were measured according to the recommendations of the American Society of Echocardiography, and LV mass was indexed to body surface area [@bb0075], [@bb0080]. A standard Doppler assessment of diastolic function was performed according to the guidelines of the American Society of Echocardiography [@bb0075], [@bb0080]. Early diastolic (E) wave velocities and atrial (A) wave velocities, and the E wave deceleration time were measured using a pulse wave Doppler recording. Septal and lateral mitral annular early diastolic velocities (E′) were measured from an apical four-chamber view using off-line color tissue Doppler images. The E = velocities from the lateral and septal annuli were averaged (E′), and E/E′ was calculated to assess LV filling pressure. The following images were obtained routinely to evaluate WMA: parasternal long axis; parasternal short axis at the level of the mitral valve, papillary muscles, and apex; apical two-, three-, and four-chamber; subcostal four-chamber; and subcostal short axis. The 16 segment model of the American Society of Echocardiography and the Regional Wall Motion Score Index (RWMSI) were used for analysis [@bb0075], [@bb0080]. The RWMSI was calculated by averaging the scores for all 16 segments, and WMA was defined as a RWMSI ≥ 1.0 [@bb0075], [@bb0080]. The frequencies of WMA were illustrated using the 16 segment model in the patients with TTC and r-TTC. A board-certified cardiologist (EW) determined the presence or absence of ST-segment changes, T-wave inversion, and the mean QTc interval for the ECG evaluation. The frequencies of ST-segment change and T-wave inversion, and mean QTc interval were compared between the two groups.

2.3. Catecholamine/biomarker measurement {#s0025}
----------------------------------------

Plasma epinephrine and norepinephrine levels were measured by high-performance liquid chromatography. The other cardiac biomarkers measured were troponin I, B-type natriuretic peptide, white blood cell count, and blood glucose levels.

2.4. Statistical analysis {#s0030}
-------------------------

Fisher\'s exact test was used to compare categorical variables, and Student\'s *t*-test was used to compare continuous variables. Linear regression analysis was performed to evaluate the correlation between plasma epinephrine and norepinephrine levels. JMP software (SAS Institute, Cary, NC, USA) was used for all statistical analyses. Numerical data are expressed as mean ± SD, and *p* \< 0.05 was considered statistically significant.

3. Results {#s0035}
==========

3.1. Background data {#s0040}
--------------------

A total of 328 consecutive patients with aneurysmal SAH underwent TTE during the 6-year study period. Among them, 21 patients with TTC and 10 with r-TTC were identified. All patients with TTC/r-TTC were ethnic Japanese. The demographic variables compared between the two groups were: age, sex ratio, frequency of WFNS grade IV/V SAH and presence of co-morbid diseases. Patients with r-TTC were significantly younger than those with TTC (51.8 ± 10.9 vs. 63.5 ± 14.4 years, *p* = 0.04) ([Table 1](#t0005){ref-type="table"}). No significant differences were observed in the other demographic variables ([Table 1](#t0005){ref-type="table"}). The physiological variables measured in the emergency department, including systolic/diastolic blood pressures, heart rates, and the frequency of pulmonary edema were compared, but no significant intergroup differences were observed ([Table 1](#t0005){ref-type="table"}). Similarly, no significant difference was observed in the frequency of patients who required the use of inotropics to maintain systemic circulation (38% in TTC vs. 50% in r-TTC, *p* = 0.70). No significant difference was detected in 90-day mortality between the TTC and r-TTC groups (33% vs. 50%, *p* = 0.45).Table 1Comparison of demographic/physiologic variables between Takotsubo cardiomyopathy and reverse Takotsubo cardiomyopathy after subarachnoid hemorrhage.Table 1TTC (n = 21)r-TTC (n = 10)*p*-ValueAge (y)63.5 ± 14.451.8 ± 10.90.04[⁎](#tf0005){ref-type="table-fn"}Male:female7:147:30.12Aneurysm locationsMCA 7, ACoA 5, ICA 5, VA 3, BA 1VA 5, ACoA 4, MCA 1N/AGrade IV/V SAH18 (86%)10 (100%)0.53Hypertension11 (52%)6 (60%)1.00Hyperlipidemia2 (10%)1 (10%)1.00Diabetes mellitus1 (5%)01.00Current smoking4 (19%)4 (40%)0.38  Systolic BP (mm Hg)163 ± 57131 ± 420.12Diastolic BP (mm Hg)96 ± 3179 ± 200.13Heart rate (bpm)97 ± 2995 ± 200.86Pulmonary edema5 (24%)5 (50%)0.22  Need for inotropic agents8 (38%)5 (50%)0.7090-day mortality7 (33%)5 (50%)0.45[^2][^3]

3.2. Echocardiographic/electrocardiographic findings {#s0045}
----------------------------------------------------

Marked differences in the frequencies of regional WMAs were revealed in basal and apical segments by comparing the 16 segment model between the patients with TTC and r-TTC ([Fig. 1](#f0005){ref-type="fig"}A, B). In contrast, no significant intergroup differences were detected in the echocardiographic parameters for systolic/diastolic functions, including LV ejection fraction, E value, E/A ratio or the E/E′ ratio ([Table 2](#t0010){ref-type="table"}). Similarly, no significant intergroup difference was detected in mean RWMSI ([Table 2](#t0010){ref-type="table"}). The frequencies of ECG abnormalities were similar between the two groups ([Table 2](#t0010){ref-type="table"}).Fig. 1Comparison of the 16 segment model between Takotsubo cardiomyopathy (TTC, A) and reverse Takotsubo cardiomyopathy (r-TTC, B) associated with subarachnoid hemorrhage revealing that there were marked differences in the frequency of regional wall motion abnormality in the apical and basal segments.Fig. 1Table 2Comparison of echocardiographic and electrocardiographic parameters between Takotsubo cardiomyopathy and reverse Takotsubo cardiomyopathy.Table 2TTC (n = 21)r-TTC (n = 10)*p*-valueLVEF (%)43.7 ± 9.739.8 ± 11.30.33LVIDd (mm)44.5 ± 7.847.1 ± 5.10.36LVIDs (mm)33.3 ± 9.638.6 ± 4.80.14LVMI (g/m^2^)116.1 ± 41.883.8 ± 14.20.16E (m/s)69.5 ± 19.264.1 ± 18.20.48A (m/s)73.2 ± 24.865.9 ± 22.70.46E/A1.07 ± 0.511.04 ± 0.380.86E′ (m/s)5.52 ± 1.906.22 ± 1.780.35E/E′13.7 ± 5.610.9 ± 4.50.19DcT (ms)189.7 ± 70.5192.2 ± 61.50.93RWMSI1.77 ± 0.351.71 ± 0.380.65  ST segment change13/21 (62%)7/10 (70%)1.00T-wave inversion6/21 (29%)1/10 (10%)0.38QTc (ms)476 ± 5463 ± 40.48[^4]

Follow-up TTEs were obtained in 11 (52%) patients with TTC and in five (50%) with r-TTC at a mean interval of 96 ± 43 h in the TTC and 91 ± 46 h in the r-TTC groups. As a result, residual WMAs were observed in eight of the 11 patients with TTC and two of the five with r-TTC ([Table 3](#t0015){ref-type="table"}). The frequencies of residual WMAs did not differ significantly (73% vs. 40%, *p* = 0.30). None of the 16 patients who underwent follow-up TTE exhibited a morphological change from one type to the other.Table 3Follow-up transthoracic echocardiography in Takotsubo cardiomyopathy and reverse Takotsubo cardiomyopathy patients.Table 3TTC (n = 21)r-TTC (n = 10)*p*-valueFollow-up TTE available11/21 (52%)5/10 (50%)1.00Interval between 1st and 2nd TTE (h)96 ± 4391 ± 460.84Residual TCM/r-TCM in 2nd TTE8/11 (73%)2/5 (40%)0.30[^5]

3.3. Catecholamine/biomarker measurement {#s0050}
----------------------------------------

Plasma epinephrine levels (pg/mL) were 380 ± 391 in the patients with TTC and 809 ± 710 in those with r-TTC (*p* = 0.04, [Fig. 2](#f0010){ref-type="fig"}A). Plasma norepinephrine levels (pg/mL) were 1724 ± 1591 in TTC and 2421 ± 1374 in r-TTC, and there was no significant difference (*p* = 0.25, [Fig. 2](#f0010){ref-type="fig"}B). The linear regression analysis showed that plasma epinephrine and norepinephrine levels were not correlated in the patients with TTC (R = 0.18, *p* = 0.447) ([Fig. 3](#f0015){ref-type="fig"}A) and weakly correlated in those with r-TTC (R = 0.57, *p* = 0.09) ([Fig. 3](#f0015){ref-type="fig"}B). No significant differences were detected in the levels of the other biomarkers ([Table 4](#t0020){ref-type="table"}).Fig. 2Plasma epinephrine levels (pg/mL) were 380 ± 391 in Takotsubo cardiomyopathy (TTC) and 809 ± 710 in reverse Takotsubo cardiomyopathy (r-TTC) patients (A). The difference was statistically significant (*p* = 0.04). Plasma norepinephrine levels (pg/mL) were 1724 ± 1591 for TTC and 2421 ± 1374 for r-TTC patients (B). The difference was not statistically significant (*p* = 0.25).Fig. 2Fig. 3Linear regression analysis showing that the plasma epinephrine and norepinephrine levels were not correlated in the 21 TTC patients (0.18, *p* = 0.447) (A). The plasma epinephrine and norepinephrine levels were weakly correlated in the 10 r-TTC patients (R = 0.57, *p* = 0.09) (B).Fig. 3Table 4Comparison of cardiac biomarker levels between Takotsubo cardiomyopathy and reverse Takotsubo cardiomyopathy.Table 4TTC (n = 21)r-TTC (n = 10)*p*-ValueTroponin I (ng/mL)2.21 ± 3.280.87 ± 0.970.28BNP (pg/mL)214.8 ± 306.8157.2 ± 192.60.71WBC (× 10^9^/L)13.6 ± 5.314.3 ± 5.90.77Blood glucose (mg/dL)198.5 ± 56.6183.2 ± 69.50.53[^6]

4. Discussion {#s0055}
=============

It is widely accepted that TTC and r-TTC share many characteristics. However, it remains controversial whether r-TTC actually differs demographically, prognostically and neurochemically from TTC. Several authors have reported that patients with r-TTC are significantly younger and have a higher prevalence of triggering stress [@bb0015], [@bb0020]. In contrast, there are patients who experienced two separate episodes of TTC and r-TTC, suggesting that TTC and r-TTC may be a temporal evolution of the same disease [@bb0025], [@bb0030], [@bb0035], [@bb0040]. Most of those studies were performed on patients with idiopathic TTC, i.e., those without neurological disease or pheochromocytoma. However, virtually no study has evaluated the potential differences between TTC and r-TTC in patients with SAH. In this regard, our study may be one of the first to report the presence of substantial differences between these two conditions. This study is also unique in that a team of cardiologists, ultrasound technicians and neurosurgeons jointly evaluated the differences between TTC and r-TTC. The frequency of r-TTC in patients without neurological disease seems to be low; Song et al. reported that the ratio of r-TTC vs. other TTC is approximately 1:4. [@bb0015]. In contrast, r-TTC in patients with SAH may occur more commonly, considering a higher r-TTC:TTC ratio of approximately 1:2 in our cohort.

We found that patients with r-TTC were significantly younger than those with TTC ([Table 1](#t0005){ref-type="table"}), which is consistent with previous studies on idiopathic TTC [@bb0015], [@bb0020]. The neurochemical profiles also differed between the patients with TTC and r-TTC ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). No cases of crossover, i.e., morphological changes from one type to the other, were found on the second follow-up TTE study. Therefore, TTC and r-TTC may not be identical neurochemically, at least in patients with SAH. From the viewpoint of clinical management, however, there may be few differences between TTC and r-TTC, except that the latter tend to be more hypotensive ([Table 1](#t0005){ref-type="table"}): neither 90-day mortality nor the need for inotropic agents differed significantly. Similarly, few differences were found in the TTE parameters or ECG findings ([Table 2](#t0010){ref-type="table"}), despite marked morphological differences on TTE. Therefore, distinguishing TTC from r-TTC may not be very important to neurosurgeons, cardiologists or intensivists for planning the treatment strategy or predicting outcomes in SAH patients. The follow-up TTE study results indicated that r-TTC may resolve more rapidly than TTC, as WMA had resolved in 60% of r-TTC patients on the second TTE performed 4 days after the first. In contrast, only 27% of TTC patients exhibited normalized cardiac wall motion. No significant differences were observed because of the small number of patients, and it remains to be seen whether speed of recovery truly differs between patients with TTC and r-TTC.

Among many neurochemical substances etiologically associated with cardiac WMA, epinephrine and norepinephrine may be the most important [@bb0060]. As plasma levels of both catecholamines are highly elevated after stressful events, such as aneurysm rupture, it is difficult to determine which catecholamine plays a more active role in the pathogenesis of TTC and/or r-TTC. Unintentional (frequently iatrogenic) epinephrine administration may provide unique insight, because many cases of iatrogenic r-TTC have been associated with exogenous epinephrine administration in the literature [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120]. Our finding of extremely elevated epinephrine levels in patients with r-TTC may also support its etiological role. The higher epinephrine--norepinephrine correlation coefficient in patients with r-TTC compared to those with TTC ([Fig. 3](#f0015){ref-type="fig"}A, B) is also reasonable. However, our findings may not be explained by the working hypothesis that a difference in the distribution of β1/β2-adrenoceptors between the apex and base, with denser β2-adrenoceptor distribution in the apex, is the reason for the greater contractile response to epinephrine in the apical myocardium with subsequent apical stunning [@bb0125]: according to this hypothesis, higher epinephrine levels would lead to typical TTC rather than to r-TTC [@bb0125]. Further clinical and experimental studies are warranted to elucidate the role of each catecholamine and its adrenoceptor in the pathogenesis of TTC and r-TTC [@bb0130].

Several limitations of this study should be mentioned. First, this was a retrospective observational study; thus, it is impossible to prove the causality of elevated epinephrine in the pathogenesis of r-TTC. Second, dichotomization into TTC and r-TTC may have been too simplistic, considering that as many as four TTC variants have been proposed [@bb0135]. Although this dichotomization has been adopted by several authors, categorical overlap might have occurred, particularly involving the mid-ventricular segments. Third, the number of patients was small: given that both conditions have low incidences making it difficult to accumulate an adequate number of samples, it may be important to establish national/international TTC registries [@bb0140]. Fourth, because of the short half-life of epinephrine, the epinephrine/norepinephrine coefficient can vary substantially with the timing of blood sample collection [@bb0145]. Finally, the follow-up TTEs were conducted in only half of the patients, and the interval between the first and second TTEs may have been too short; therefore, it may be too early to conclude that a morphological change from one type to the other does not occur in patients with SAH.

5. Conclusion {#s0060}
=============

Patients with SAH-induced r-TTC were significantly younger and exhibited higher plasma epinephrine levels than those with SAH-induced TTC. These results suggest that the pathomechanisms of the two conditions may not be identical. However, distinguishing between TTC and r-TTC in patients with SAH may not have great importance from the standpoint of clinical management and prognostication.
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